Cadrenal Therapeutics, Inc. 8-K

What Happened Cadrenal Therapeutics, Inc. (CVKD) filed an 8-K on February 24, 2026 furnishing a press release reporting results from a randomized, blinded, placebo‑controlled Phase 2 trial of CAD-1005 (formerly VLX‑1005) in patients with heparin‑induced thrombocytopenia (HIT). CAD-1005 is a selective 12‑lipoxygenase (12‑LOX) inhibitor. The trial — completed in December 2025 after program ownership transferred from Veralox Therapeutics, Inc. to Cadrenal — did not meet its primary endpoint: platelet count recovery rate was similar between CAD-1005 and placebo. However, the key secondary endpoint showed fewer new or worsening thrombotic events in the CAD-1005 group (50%) versus a high rate in the placebo group (>75%). The study was not powered to demonstrate statistical significance on that endpoint. The press release is furnished as Exhibit 99.1 to the 8-K.

Key Details

• Filing date: February 24, 2026; trial concluded December 2025 after ownership transfer from Veralox to Cadrenal.
• Primary endpoint (platelet count recovery rate): no meaningful difference between CAD-1005 and placebo.
• Key secondary endpoint (new/worsening thrombotic events): CAD-1005 group 50% vs placebo >75%; study not powered for statistical significance.
• Drug mechanism: CAD-1005 is a selective 12‑LOX inhibitor intended to block immune mechanisms driving HIT.

Why It Matters For investors, the filing highlights mixed Phase 2 data: the trial failed its chosen primary endpoint but showed a potentially clinically relevant signal of fewer thrombotic events with CAD-1005 when added to standard anticoagulants. That secondary finding could influence Cadrenal’s development strategy and the design of any follow‑on trials or discussions with regulators, but it is preliminary and not conclusive because the study was not powered to prove significance. The 8-K contains no financial results or management changes; it simply furnishes the company’s press release about the trial outcome.